DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,673,237 | +60.6% | 30,928 | +55.3% | 0.11% | +60.6% |
Q2 2023 | $4,778,160 | -7.6% | 19,909 | -3.0% | 0.07% | -12.3% |
Q1 2023 | $5,172,617 | -24.7% | 20,523 | -20.7% | 0.08% | -27.7% |
Q4 2022 | $6,873,316 | -7.0% | 25,896 | -9.5% | 0.11% | -19.4% |
Q3 2022 | $7,388,000 | +16.3% | 28,603 | +14.2% | 0.14% | +18.8% |
Q2 2022 | $6,352,000 | +2.1% | 25,057 | +18.2% | 0.12% | +13.6% |
Q1 2022 | $6,219,000 | -8.3% | 21,201 | +2.8% | 0.10% | -14.2% |
Q4 2021 | $6,785,000 | -38.3% | 20,621 | -42.9% | 0.12% | -46.7% |
Q3 2021 | $11,003,000 | +26.5% | 36,112 | +11.4% | 0.22% | +30.1% |
Q2 2021 | $8,700,000 | -0.1% | 32,428 | -16.2% | 0.17% | -10.4% |
Q1 2021 | $8,705,000 | -1.9% | 38,692 | -3.2% | 0.19% | -20.2% |
Q4 2020 | $8,878,000 | +384.9% | 39,972 | +370.1% | 0.24% | +340.0% |
Q3 2020 | $1,831,000 | +114.4% | 8,502 | +76.1% | 0.06% | +111.5% |
Q2 2020 | $854,000 | +611.7% | 4,827 | +458.0% | 0.03% | +550.0% |
Q1 2020 | $120,000 | -23.1% | 865 | -14.7% | 0.00% | +33.3% |
Q4 2019 | $156,000 | +3800.0% | 1,014 | +3171.0% | 0.00% | – |
Q3 2019 | $4,000 | – | 31 | +3000.0% | 0.00% | – |
Q2 2019 | $0 | – | 1 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |